1 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018916)
|
2 |
WO patent application no. 2013,0667,53, Compositions useful for the treatment of viral diseases.
|
3 |
Clinical pipeline report, company report or official report of Hemispherx Biopharma.
|
4 |
Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
|
5 |
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
|
6 |
Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
|
7 |
WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
|
8 |
Clinical pipeline report, company report or official report of Genentech (2011).
|
9 |
Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
|
10 |
Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
|
11 |
Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
|
12 |
Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
|
|
|
|
|
|
|